Sources of Vitamin D and Prevalence of Deficiencies
Vitamin D is present in relatively small amounts in the typical Western diet. Its primary food sources are oily fish such as salmon and food fortification (where it is supplied as D2/ergocalciferol, thought by some authors to be a less potent form than the more typical supplements of D3/cholecalciferol). 1 This potency issue is disputed by some authors. 2 The predominant production and source of vitamin D in humans occurs through sunlight exposure. Solar ultraviolet B radiation (wavelength, 290-315 nm) penetrates the skin and converts 7-dehydrocholesterol to previtamin D, which is rapidly converted to vitamin D3. Excessive sunlight exposure will not cause vitamin D toxicity (though it can cause various types of skin damage, see below), because any excess previtamin D3 or vitamin D3 is destroyed by sunlight. In more temperate climates, during the winter months, the UVB exposure is so minimal that virtually no vitamin D is formed. A study by Webb et al showed that no previtamin D3 was formed when human skin (or 3 alpha-3H 7-dehydrocholesterol) was exposed to sunlight on cloudless days in Boston (42.2 degrees N) from November through February. In Edmonton (52 degrees N) this ineffective winter period extended from October through March. 3 Lifestyle modifications with decreased outdoor time, and the tendency for skin coverage with clothing or sunscreens, have greatly exaggerated this modern dynamic of decreased exposure to sunlight.
Vitamin D relative insufficiency and frank deficiency are extremely common. Although opinions differ as to what constitutes adequate and optimal levels of vitamin D (determined by measurements of 25-OH D, the main circulating form), deficiency is usually defined as ≤19 ng/mL, and insufficiency as between 20 and 29 ng/mL. (Note that most labs report levels in ng/mL, whereas many studies report mmol/L; 30 ng/mL is equivalent to 75 mmol/L.) Further detailed discussion as to what constitutes adequacy or optimal levels in different clinical contexts is given below. In Israel, a country with substantial sun exposure, significant vitamin D deficiency (serum 25-OH D < 15 ng/mL) was found in 26.27% of hospitalized patients. 4 In a study of 290 hospitalized patients on a general medical floor in Boston, vitamin D insufficiency was detected in 164 patients (57%), of whom 65% were very severely deficient (serum 25-OH D concentrations <8 ng/mL [20 nmol/L]) 5 . A study in Italy found that an almost unbelievable 83% of postmenopausal female patients with prolonged hospitalizations were severely deficient. 6 A French study likewise found that 82% of inpatients were vitamin D deficient and 20% had elevated parathyroid levels consistent with secondary hyperparathyroidism. 7 Elderly and immobilized patients have up to a 50% incidence of secondary hyperparathyroidism. 8 In a Boston outpatient thyroid clinic, winter measurements showed gross deficiency in 14% and insufficiency in 53% of attendees. 9 The above findings make it clear that vitamin D deficiency, in the healthy and ill, in outpatients and inpatients, in sunny countries and those countries with less sun exposure, is a serious and widespread problem in the modern world (Table 1) .
Considering the extremely wide prevalence of deficiencies, these studies suggest that as a general clinical approach in Europe and North America, the possibility of vitamin D deficiency should be suspected and tested for in most, if not all, patients. The most important predisposing factors, as elucidated above, are modern lifestyle modifications leading to decreased sun exposure (indoor work and lifestyle) and decreased sun penetration (excess sunscreen and clothing). There are other individual and environmental factors that increase the likelihood of developing vitamin D deficiency. These include conditions that decrease light penetration, such as obesity and darker pigmented skin, as well as living at a higher latitude or in an overcast environment.
"Adequate" and "Optimal" Vitamin D Levels
The determination of what constitutes vitamin D adequacy has typically been based on musculoskeletal considerations. Parathyroid hormone (PTH) levels are in the high normal range or frankly increased when 25-OH values are less than 30 ng/mL, often leading to a state of secondary hyperparathyroidism when 25-OH levels are in deficient ranges. 7, 8 Even when PTH levels are in the normal range, they will decrease when the 25-OH D levels are increased and normalized. As 25-OH vitamin D levels are raised to between 30 and 40 ng/mL (75-90 nmol/L), the PTH levels plateau at a nadir. Therefore, regarding bone health and the prevention of osteomalacia and osteoporosis, 30 to 40 ng/mL is generally considered an adequate level. There are many relevant extra-skeletal actions of vitamin D which are of importance for the prevention and possibly treatment of malignancies, as well as for effects on immune functioning and autoimmune diseases. 10 Optimal levels of 25-OH D for these clinical situations might differ from those considered optimal for skeletal considerations.
Regarding malignancies, 1,25-OH Vit D has significant proapoptotic, antimetastatic, antiangiogenic, growth cycle inhibitory, immune modulating, and prodifferentiating effects. [10] [11] [12] These actions occur both systemically, as well as in local tissues, where production of 1,25-OH Vit D (the biologically active form of vitamin D) takes place in organs such as colon, breast, and lung (all of which have vitamin D receptors), when locally occurring hydroxylases convert 25-OH Vit D to 1,25-OH Vit D, in response to local needs, conditions, and factors. As the factors leading to the production of 1,25-OH D are different systemically (skeletal needs) than those occurring locally (dedifferentiation, angiogenesis, etc.) the optimal level of 25-OH D for these extraskeletal actions might therefore be different from that required for systemic bone health. For instance, in a situation where premalignant cells are present in an organ such as the colon, the patient might benefit from a higher level of local 1,25-OH vitamin D production, with its attendant antimalignant actions, than the level generally required for bone formation, or in normal tissues without premalignant cells. The optimal level can be suspected to be at least 40 to 50 ng/mL as shown by the inverse relationship of the incidence of malignancies with 25-OH levels. 11 Many studies only go as far as defining the upper quintile as >30 to 40 ng/mL (some define the upper quintile at a much lower level, such as >20 ng/mL). These studies often do not give adequate information about individuals with higher levels of 25-OH D. Since cancer risk appears to decrease in a linear fashion between each quintile, it is reasonable to suspect that this linear decreased risk will continue, at least to some degree, at higher levels of 25-OH D concentrations. 12 pooled studies involving 1760 women looking at breast cancer risk and found a 50% decreased risk when comparing the group in the quintile of 25-OH D levels >52 ng/mL with the lowest quintile of <13 ng/mL. In 2007, there were 180 000 cases of breast cancer diagnosed in the United States. One could project a very significant decrease in this number if these findings are true and vitamin D levels were increased in the general population.
As there is a wide safety net before vitamin D toxicity would potentially manifest (usually >75-100 ng/L), some clinicians and investigators consider it reasonable to routinely attempt to have patients attain 25-OH D levels of at least 40 to 50 ng/mL. If there are no changes in the usual dietary patterns and sun exposure for Western populations, supplementation of vitamin D3 in the amount of about 4000 IU/d is usually required to attain these levels. As an alternative, oral intake of 2000 IU/d and 12 minutes of full sun exposure of 50% of the body surface could achieve the same levels. This amount of sun exposure is 60% of the minimal erythema dose, and except for sun sensitive individuals, or those taking medications increasing photosensitivity, is very safe. 12 Contrary to widely held misconceptions, 2000 to 4000 IU/d is a very safe dosage, particularly if followed prudently with 3 monthly 25-OH Vit D determinations. 13 These considerations are in stark contrast to the usually recommended daily requirements of vitamin D and levels that should be attained, and suggest that the official recommendations are too low and should be reconsidered and increased.
Vitamin D Levels and the Occurrence of Malignancies
In the past few years, studies have appeared with increasing frequency showing an inverse relationship of 25-OH D levels with the incidence and mortality of malignancies. 14 Surrogate measures for vitamin D production (latitude, amount of sun exposure) as well as actual measurements of 25-OH Vit D have confirmed this inverse relationship for a wide range of malignancies, including colon, breast, ovarian, lung, non-Hodgkin's lymphoma, pancreas, endometrial, renal, and multiple myeloma. 10 As noted above, patients with serum 25-OH D of approximately 52 ng/mL had a 50% lower risk for breast cancer than those with levels less than 13 ng/mL. 14 Another study showed an even greater decrease in the risk of developing colorectal cancer. 15 Individuals with a level of 34 ng/mL developed colorectal malignancies half as frequently as those with a level of 6 ng/mL. Achieving a level of 46 ng/mL was projected to decrease the incidence by 66%. Giovannucci et al found a significant decrease in GI and total cancer incidence and mortality as estimated vitamin D levels increased. 16 An increment of 25 nmol/L (10 ng/mL) in the estimated blood level of vitamin D was associated with a 17% reduction in total cancer incidence, a 29% reduction in total cancer mortality, and a 45% reduction in digestive system cancer mortality (see Table 2 ). A study reporting relative risk in context of a randomized trial of vitamin D and calcium supplementation found an even greater reduction in cancer incidence: 35% per 10 ng/mL increase in the 25-OH vit D levels. 17
Potential Effects on Aggressiveness of Malignancies
In addition to the incidence of malignancies, their aggressiveness and tendency to form metastases might also be effected by vitamin D. Nakagawa et al reported a marked inhibition of metastatic activity in an animal model. 18 Pendas-Franco et al found that 1,25-OH Vit D changed the phenotype of breast cancer cells to a less aggressive form. 19 Palmieri et al found a higher 25-OH D level in breast cancer patients who presented with early as opposed to advanced disease. 20 Zheng et al, in a murine model, found that calcium deficiency and high bone turnover (one of the causes of which is vitamin D deficiency) is associated with an increased incidence of bone metastases. 21 The above findings suggest that in addition to decreasing the overall incidence of malignancies, vitamin D might also decrease the aggressiveness of those tumors that do occur (see discussion on melanoma below).
Supplementation With Vitamin D
The above studies establish the relationship of vitamin D levels with the incidence and mortality of various malignancies. By themselves, they don't confirm a causal effect. To investigate causality, studies must look at supplementation or intake of vitamin D and the effect on the incidence and mortality of malignancies. Grant et al, combining findings from a metaanalysis as well as the findings in a multifactorial ecologic study of cancer mortality rates in Vitamin D and Integrative Oncology / Cantor 83 the United States, estimated that supplementation of 1000 IU of Vit D3 could lead to reductions in cancer incidence of 7% for males and 9% for females in the United States and 14% for males and 20% for females in Western European countries living below 59 degrees latitude. 22 In a prospective study following cohorts of over 100 000 participants, Skinner found that intake of 400 IU vitamin D3 as ascertained by food frequency questionnaires led to a 43% decreased incidence of pancreatic cancer. 23 A widely publicized prospective observational trial was conducted by Freedman et al at the National Cancer Institute, examining the relationship between levels of 25-OH vitamin D in individuals at study entry and subsequent cancer mortality. 24 This study concluded, "Our results do not support an association between 25-OH D and total cancer mortality, although there was an inverse relationship between 25-OH D levels and colorectal cancer mortality." The study followed patients 17 years and older for 6 to 10 years. There are critical faults in the study design which likely lessened the expected relationship of 25-OH Vit D levels and mortality from malignancies. The most critical fault is that while cancer mortality was measured, cancer incidence was not measured or reported. This was a serious omission in a study looking at a population of patients with a wide range of ages (some only 17 years old), who were followed for the relatively short time of 6 to 10 years. Consequently, if a patient was too young to be expected to develop cancer (<35-40 years old at study entry), or if they did develop a malignancy, but did not die from it (as would be expected for many of the most common cancers, or if the participant developed the malignancy towards the end of the 6-10 year observational period), the study would not capture these patients. Considering these flaws in the study design, it is striking that participants who had 25-OH D levels >30 ng/mL on study entry died from colon cancer at a statistically significant 70% lower frequency than those whose levels on entry were <20 ng/mL. A similar trend, although not statistically significant, was found for breast cancer mortality. Unfortunately, the "headline" that emerged from this study was that there was no relationship between vitamin D levels and overall cancer mortality, a clearly misleading conclusion. There have been 2 interventional randomized, double blind, controlled studies exploring the use of vitamin D supplementation and the development of malignancies. A randomized, double blind placebo controlled study was conducted by Wactawski-Wende et al 25 where 36 000 postmenopausal women were randomized to placebo or treatment with 500 mg calcium carbonate and a low dose of 400 IU vitamin D3 and followed for 7 years. The study concluded, "Daily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women." A close look at the study reveals critical problems in the study design. The intervention of 400 IU would not be expected to have a significant effect on 25-OH D levels. Many participants receiving this dose would be expected to have levels below 30 ng/mL, below the "adequate" range, and far below levels considered more optimal for malignancy prevention as discussed above. It is generally considered that supplementation of at least 800 IU is required to reach levels of 30 to 40 ng/mL, whereas supplementation in the ranges of 1000 to 4000 IU is expected to allow 25-OH D levels of >40 ng/mL to be attained. Perhaps the most interesting finding in this study was that participants who entered the study with 25-OH D levels <12 ng/mL developed colon cancer 2.5 times more frequently than those whose 25-OH D levels at study entry were >25 ng/mL. The only appropriate conclusion to be made from this study was that low dose supplementation of 400 IU Vit D3 had no effect on the subsequent development of colon cancer in this cohort. This, unfortunately, was not the message that was generally portrayed in short news summaries of this study. On the other hand, a double blind, randomized placebo controlled interventional study by Lappe et al found that a group of postmenopausal women treated with the higher dose of 1000 IU vitamin D and calcium had a relative risk of 0.232 (CI: 0.09, 0.60; P < .005) of developing a malignancy (nonmelanoma skin cancer excluded) compared to a placebo group not taking Vit D. 17 It was not clear if the calcium interacted with the protective effect of vitamin D. The benefit from vitamin D appeared to be independent of other interventions.
Effects of Seasonal Variation and Vitamin D on Prognosis
A recent group of ecological studies, some using surrogate measures of vitamin D levels, has shown a direct relationship between season of diagnosis and survival in non-small cell lung cancer (NSCLC). Zhou et al found that early stage patients who had high intakes of vitamin D and had surgery in sunny months were more than twice as likely to be alive 5 years after surgery compared to those patients with low levels of vitamin D intake who had surgery in the winter (hazard ratio [HR] 0.30; 95% CI, 0.13-0.70; P trend <.01) while 5 year relapse-free survival was 56% vs. 23%, respectively. 26 Lim et al found evidence of substantial seasonality in cancer survival, with diagnosis in summer and autumn (times of higher sunlight exposure, a surrogate marker of Vit D status) associated with improved survival compared with that in winter, especially in female breast cancer patients and lung cancer patients of both sexes (HR 0.86, 0.95, and 0.95, respectively). 27 Zhou et al carried his investigations further with his non-small cell lung cancer cohort and, when measuring 25-OH D levels and vitamin D intake, found that vitamin D levels may be associated with improved survival of patients with early-stage NSCLC, particularly among stage IB-IIB patients. 28 These studies suggest that a potential explanation accounting for these findings is that vitamin D works additively or synergistically with the treatment protocols for non-small cell lung cancer. There are, of course, other plausible hypotheses. This suggestion raises an interesting and clinically relevant question⎯can vit D compounds be used not only as preventive agents, but as therapeutic agents in already established disease.
Interactions Between Chemotherapy, Radiation Therapy, and Vitamin D
There is always concern in the field of oncology that adding substances like vitamins to radiation therapy and chemotherapeutic protocols might have a negative effect. For example, there are related concerns of vitamin and possibly antioxidant interference with chemo/radiation therapy. It should be noted that the evidence-based literature (which is relatively sparse) is not supportive of this general concern, 29 though appropriate theoretical concerns exist. The known actions of vitamin D (antiproliferative, antiangiogenic, antimetastatic, proapoptotic, prooxidant, immunomodulatory, prodifferentiating) do not suggest that interference would occur with this agent, as opposed to agents like vitamin E which have more focused, antioxidative actions. To date, very few studies have looked at interactions between vitamin D and chemotherapeutic agents. Wigingtton et al noted 1,24 (OH)2 D2 produced synergistic effects with doxorubicin, carboplatin, and cisplatin and additive effects with busulfan, etoposide, tamoxifen, 5-fluorouracil, and carboplatin in cell culture studies. 30 Pelczynska et al found in vitro studies showed synergism between vitamin D and chemotherapeutic agents. 31 Studies by Beer et al in prostate cancer patients (discussed below) using calcitriol and Taxotere ® didn't suggest any interference, but rather potential additive efficacy. 32 Collectively, these studies help in a small way to allay concerns of negative interactions between vitamin D and conventional treatment methods. With the growing interest in vitamin D and oncology, we would hope and expect that future studies further clarify this important issue.
Vitamin D as an Active Cancer Treatment Agent
Numerous investigators have looked at the use of vitamin D compounds as part of treatment programs in patients with established malignancies. Some studies have been encouraging. Trouillas treated 10 patients with glioblastoma multiforme in a phase 2 study, adding alfacalcidol (1-OH D, a synthetic vitamin D analogue) to standard treatment protocols (surgery, radiation therapy, and chemotherapy) whereby 2/10 had long term >4 year survival. 33 Follow-up studies have not been published. Woo et al studied asymptomatic prostate cancer patients with biochemical PSA relapse. He found that the median PSA doubling time increased from 14.3 to 25 months after commencing 2000 IU/d vitamin D3 supplementation. 34 In a very small study, Gross et al treated prostate cancer patients with 0.5 mcg/d of 1,25-OH vitamin D (calcitriol) and found that the rate of PSA rise during versus before Vit D therapy significantly decreased in 6 of 7 patients. Some patients developed hypercalcemia. 35 In attempting to avoid the adverse effect of hypercalcemia, Beer et al studied the use of high dose calcitriol given once weekly. Beer et al also studied prostate cancer patients who had become resistant to hormonal manipulation treatment with androgen blocking agents. One group received Taxotere 3 out of 4 weeks while the other group received Taxotere and weekly calcitriol at the very high dose of 45 mcg (approximately 0.5 mcg/kg). The primary endpoint, PSA response, showed a nonstatistically significant trend in favor of the calcitriol group. Median survival (which was not a primary endpoint) had not been reached for the calcitriol arm and was estimated to be 24.5 months, compared with 16.4 months for the placebo group. 36 Toxicity was decreased in the treatment versus control group, despite the high weekly calcitriol dose. An important issue needs to be pointed out in the prostate cancer studies. Most tissues are able to convert 25-OH D to 1,25-OH D. Prostate cancer cells, as opposed to, for instance, colon cancer cells, lose this ability. As Giovannucci notes, this can explain the inability of some studies to show a relationship of circulating 25-OH D levels with prostate cancer, whereas other studies show an inverse relationship with 1,25-OH levels. 37 It is conceivable that in prostate cancer, treatment with 25-OH D3 might be less effective than treatment with the active form 1,25-OH D due to this difficulty in conversion. When using 1,25-OH D3, issues of potential toxicity arise, and regimens such as high weekly doses as employed by Beer et al represent a successful attempt to minimize this toxicity.
Melanoma and Skin Cancer
Our society has become obsessed with shielding of the skin from sun exposure. The resultant behavioral patterns have contributed significantly to the widespread vitamin D deficiency. To assess this concern with sun exposure appropriately, the risk factors for melanoma and nonmelanoma skin cancer, and the prevalence of these illnesses needs to be understood.
Whereas the less worrisome nonmelanoma skin cancers such as basal and squamous cell carcinomas are associated with cumulative sun exposure, melanoma is not associated with cumulative sun exposure. Melanoma is associated with intermittent and intense sun exposure, and especially with sunburn in areas not typically exposed to the sun, such as the back in males, and the legs in females. Blistering sunburns, especially if they occur in childhood, are associated with an increased risk of developing melanoma. A history of 5 sunburns in childhood is associated with a twofold increase in subsequent development of melanoma. The above risk factors, interestingly, apply only to the non-Hispanic white population, not to people of African-American, Asian, Hispanic, or Native American descent.
Changing patterns of habitation are important risk factors for melanoma, particularly when Caucasians live in warmer climates with higher sun exposure. The highest incidence of melanoma occurs in Australia and New Zealand, where a light-skinned, primarily Celtic population lives in an area of high sun exposure. Evolution has obviously not prepared them for this level of sun exposure.
Although the incidence of melanoma has increased dramatically in the last 20 years, mortality has increased to a much smaller degree. This is no doubt due to increased awareness, and earlier and increasing rates of diagnosis and biopsy (leading both to a higher diagnosis and incidence rate, as well as a higher cure rate). While 60 000 cases of melanoma in the United States are now diagnosed yearly, the corresponding mortality is 8000 per
year. An individual, on average, has a 0.25% lifetime risk of dying from melanoma. This number pales in comparison to the prevalence of the malignancies mentioned above (consider that in 2007, 180 000 cases of breast cancer alone were diagnosed in the United States, with a mortality of 40 000). Without minimizing the seriousness of melanoma, particularly if diagnosed at an advanced stage, the decreased sun exposure and poorer vitamin D status that has resulted from the public fear must be considered in the wider context of malignancies as a whole.
A study by Berwick et al suggests that higher chronic sun exposure (and by inference higher vitamin D levels) actually protects against melanoma mortality. 38 One plausible reason for this finding is that this group of patients with chronic exposure have a higher vitamin D level, with its numerous antimalignant properties, and potentially decreased aggressiveness, as discussed above. The concerning paradox implied in this observation is that many people who are drastically limiting their sun exposure in daily life, go on vacation and get inadequately shielded, severe short term sun exposure. If the above finding is confirmed, they would be better served by getting prudent chronic sun exposure in their daily life, which would be protective against the more intense exposure occurring during vacations. This pattern of behavior, according to the understood etiology of melanoma, would not lead to an increased incidence of melanoma, but could conceivably lead to a lowered aggressiveness of and mortality from this disease.
It can be seen from the above that the blanket recommendation of sun protection, as far as melanoma is concerned (as opposed to other skin cancers), is misplaced. It is clear that intermittent, extreme sun exposure, especially in individuals who do not typically have significant and frequent sun exposure, is worrisome. Unfortunately the public has the misperception that sunshine is bad. Judging from the information on vitamin D, this is obviously a much more complex situation.
Potential Concerns
A few studies raised concerns about high vitamin D levels. A Chinese study by Chen et al 39 compared quintiles of 25-OH D levels and paradoxically found a direct relationship of higher levels and the development of esophageal carcinoma in males. It should be noted that all the participants, including those at the highest levels, were actually vitamin D deficient. The 75th percentile was 20 ng/mL. Stolzenberg-Solomon et al reanalyzed the ATBC trial and found that those with higher levels of 25-OH D had an increased incidence of pancreatic cancer. 40 Tuohimma et al found that both low (<8 ng/mL) and higher (>35 ng/mL) 25-OH D levels were associated with an increased incidence of prostate cancer. 41 In this context, one can consider the comments of Giovannucci discussed above on the inability of prostate cancer cells to hydroxylate 25-OH D to 1,25-OH D. He suggests that 1,25-OH D might be more important than 25-OH D for poorly differentiated prostatic malignancies. 37 Another interesting issue is raised by Dizdar et al in a letter to the editor. They note that vitamin D is a potent stimulator of the cytochrome p450 gene that metabolizes aromatase inhibitors, and raise concerns about concurrent use of vitamin D and aromatase inhibitors. 42 Though these papers raise concerns and deserve continued attention, they seem to involve distinct populations, as in the esophageal cancer studies, and the potentially unique situation of prostate cancer. Dizdar et al raise an interesting point that bears following through. Clearly, most studies suggest that higher vitamin D levels are associated with a decreased incidence of most malignancies.
The issue of vitamin D toxicity, and most especially hypercalcemia, is one of potential concern. A review article by Vieth 13 shows that this is very uncommon when using vitamin D3 (cholecalciferol) except in situations of very high levels of supplementation (>10,000 IU) over extended time periods. A study by Wu et al showed that 50 000 IU D/daily for 10 days was safe. 43 The use of very high, pulse doses of vitamin D (up to 500 000 IU), given as a single dose to rapidly elevate 25-OH D levels, has been demonstrated to be safe by Bacon et al. 44 As opposed to 25-OH D3, the use of 1,25-OH Vit D is associated with toxicity, particularly if used on a daily basis. This was illustrated in the prostate cancer study by Gross et al. 35 On the other hand, the use of very high weekly doses of 1,25-OH D in the hormone resistant prostate cancer patients 36 did not demonstrate increased toxicity, and patients showed increased treatment tolerance. A great deal of work has been done to develop vitamin D analogues which have low toxicity.
Hypercalcemia, which is the most worrisome potential complication of vitamin D toxicity, is a relatively common occurrence in cancer patients. Caution suggests very judicious use of vitamin D in these contexts, as theoretically, due to the increased intestinal absorption, decreased renal excretion and decreased bone resorption of calcium induced by vitamin D, further hypercalcemia can result. No studies have been able to be identified in this connection.
Some Musings on Light, Vitamin D, and Integrative Oncology
A well known and wise anthroposophical physician, Otto Wolff, described vitamin D as "materialized, or transformed light". This is a profound and creative perception, though not a comprehensive description of light. As integrative, holistic oncologists, we pay attention with our patients, to factors not adequately considered by many physicians. We speak about diet, about exercise and activity, about stress, hope, and meaning. Though these aspects of life, and of healing, are difficult to quantify, we know they are important, certainly for quality of life, and probably for healing of illness. But we rarely speak of light as a healing factor. So much of our life today is enclosed and cut off from light⎯we work mostly indoors, and in our recreational lives outdoors, our fear of skin cancer leads us to cover ourselves with clothes, hats, and ointments. It's estimated that, on an average, only 5% of our skin is typically exposed to sunlight when we're outdoors. 13 As described above, we get vitamin D from two natural sources: (1) sunlight and (2) foods that have a high heat or warmth capacity (oils from fish). From this, we can already see that the description of vitamin D as "materialized, or transformed light" must also include "transformed warmth," since sunlight provides both light and warmth.
We require vitamin D for an extremely wide range of healthy functions. Sunlight, however, is related to more than vitamin D. Physiologically, we know that light (and darkness) have profound relationships with melatonin, a substance with many functions that are relevant to the field of oncology. 45 Melatonin is a medication many integrative oncologists use frequently, with encouraging and supportive medical studies substantiating its usage. 46 It is a paradox that these two substances, vitamin D and melatonin, both with important relationships to malignancies, have opposite relationships to light and darkness. Our relationships to sunlight during the day, and our relationship to darkness during the night, having much to do with the rhythm of our life, are both dysfunctional. Light is important for many mood disorders, especially seasonal affective disorder. Light is used as a medical treatment in disorders such as cutaneous T cell lymphoma and graft versus host disease, in the form of extra corporeal photopheresis. Light therapy is used for the treatment of severe psoriasis.
The relationship of vitamin D to light is somewhat analogous to the relationship of vitamins to food. Using vitamin D or vitamin supplements is not the same as going out into sunlight or eating wholesome healthy food. On the other hand, in general we cannot get as focused a therapeutic effect by eating a well balanced healthy diet, as we can if we eat this type of diet and supplement it with appropriate doses of carefully chosen supplements. It is also not possible, for many commonly used supplements, to obtain equally high amounts through our diet as we can through supplementation.
We can, however, produce very high (though not toxic) levels of vitamin D through sun exposure. 13 What prevents this is our lifestyle, and our fear of skin cancers (particularly melanoma). The ability of people to travel easily to different climates has complicated further an already complex situation, as we find that light skinned people, who have been in climates with less sun exposure for millennia, can now travel to climates with a much higher sun exposure, and are therefore at higher risk for adverse reactions and skin cancer development. The opposite situation applies to darker skinned races, such as Hispanics and African Americans. These people have traditionally lived in areas with high sun exposure. As they move to areas with less sun exposure, their skin pigmentation leads to decreased light absorption, and a lower vitamin D production, which may be causally related to a generally higher level of malignancies, particularly in African-Americans. Returning to analogies with food, although we know that certain diets, such as an Asian diet, are healthy for Asians, this does not necessarily translate into a strict Asian diet being healthy, or socially plausible, for westerners. In the same way, it is probably unhealthy for an individual of Northern European or Anglo/Irish ancestry to have the identical levels of sun exposure in the tropics as people from cultures indigenous to tropical climates.
As physicians, we need to contemplate and try to make sense of these complexities, and then attempt to help our patients. The bulk of this paper describes the beneficial properties and effects of vitamin D. We need to extend our prescriptions with our patients to also include the beneficial effects of light (and darkness), warmth, rhythm, and sunshine, in the same way that we encourage healthy balanced diets along with substantial doses of carefully chosen supplements, be they vitamins, minerals, or herbs.
The importance of exposure to sunlight has been intuitively recognized for millennia. This is expressed in the quote by Flying Hawk at the beginning of this article. Likewiseas it is stated in Genesis 1:3-4, "God said, Let there be light: and there was light. And God saw the light, that it was good." He, and we, just have to make certain changes to adapt this to our life in the 21st century.
Summary
1. There appears to be a clear inverse relationship of vitamin D levels (measured as 25-OH Vit D) and the incidence and mortality of numerous malignancies. These are confirmed primarily in retrospective epidemiological studies. One large prospective study demonstrated a significant decrease in mortality from colorectal malignancies. Total mortality was not decreased, but numerous flaws in the study design might have disguised this effect. 2. A well designed intervention study, using moderate and safe doses of vitamin D, investigating the prevention of malignancies, has shown significant reductions in their occurrence. These effects have appeared within a relatively short period of time after beginning this intervention. One poorly designed intervention study, using a low Vit D dose of 400 IU, did not demonstrate any decreased incidence. 3. Limited treatment studies of different forms of vitamin D (both alone and in conjunction with conventional treatments) in patients with already established malignancies (primarily prostate cancer) have been generally suggestive of a benefit. 4. Provocative ecological studies have suggested a direct relationship between vitamin D levels (determined by 25-OH levels, or by surrogate markers such as seasonal occurrence) and disease survival. These suggest that there is an interaction between vitamin D and the conventional treatments employed. There are various scenarios that could explain this association. Vitamin D might have a beneficial effect on processes such as protection from infections and treatment adverse effects, allowing the patients to obtain and tolerate treatments better. It is also conceivable that the vitamin D might have antitumor effects that are additive or synergistic with the conventional treatments. Considering the wide range of relevant physiological effects of vitamin D (antiinflammatory, prodifferentiating, proapoptotic, antiangiogenic, immunomodulatory, antimetastatic), this scenario could easily be envisioned.
Clinical Recommendations
1. With the significant preventive effect on multiple malignancies, consideration should be given to the measurement of 25-OH levels in most (if not all) patients, just as we routinely measure lipids for cardiovascular prevention. An alternative consideration would be to increase the recommended daily levels to at least 2000 IU/d and possibly 4000 IU/d. 13 Blood levels would still need to be checked in order to monitor this intervention, as significant individual variations occur. 2. Levels of at least 30 to 40 ng/mL should be attained, either through dietary, environmental, or supplementation means, or a combination of these. To this effect, 4000 IU/d is a safe dose. Patients also need to have an adequate calcium intake, either through diet or supplements.
3. Different clinical situations should dictate the optimal levels. Those at high risk for malignancies, or with already established malignancies should attain levels of ≥50 ng/mL. 4. In patients with newly diagnosed malignancies, significant consideration should be given to rapidly optimize 25-OH levels. Regimens have been reported that can quickly, safely, and substantially improve 25-OH vitamin D levels. 43, 44 
